European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative diseaseSeptember 25, 2026Read article
FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDGSeptember 23, 2026Read article
Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)September 9, 2026Read article
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebralSeptember 8, 2026Read article
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 8, 2026Read article
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsSeptember 8, 2026Read article
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of DirectorsSeptember 8, 2026Read article
Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDGMay 13, 2026Read article
Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsMay 13, 2026Read article
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 13, 2026Read article
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsMay 13, 2026Read article
